FDA approves Ultragenyx drug for rare enzyme disorder

(Reuters) – The U.S. Food and Drug Administration approved on Wednesday a new treatment made by Ultragenyx Pharmaceutical Inc for a rare genetic disorder that can dramatically reduce life expectancy.


Source: Reuters Health News